The RNA-binding protein La/SSB is associated with HNSCC progression and TFAP2C/FSCN1-linked transcriptional regulation Authors: Shixian Liu, Deshang Chen, Wentao Zhang, Hui Li, Jie Peng, Xiaomin Wang, Mingjie Zhang, Weiwei Liu, Junjie Zhang, Mengjun Wang, Guoying Han, Changqi Cai, Shencheng Liu, Xiaoli You, Qun Xu, Yuefeng Han, Xiaojun Zha, Shiyin Ma Published: 2026 ABSTRACT Head and neck squamous cell carcinoma (HNSCC) is characterized by aggressive progression, frequent therapeutic resistance, and poor clinical outcomes. Although the RNA-binding protein La/SSB is aberrantly expressed in multiple malignancies, its functional and mechanistic role in HNSCC remains incompletely understood. Here, by integrating transcriptomic and chromatin accessibility profiling with comprehensive in vitro and in vivo analyses, we identify La/SSB as a putative regulator associated with HNSCC progression and cisplatin (CDDP) resistance. La/SSB was markedly upregulated in HNSCC tissues and cell lines, and elevated expression was associated with unfavorable survival. Genetic depletion of La/SSB suppressed proliferation, migration, and invasion, promoted apoptosis, and reduced tumor growth and metastatic colonization, whereas ectopic expression exerted the opposite effects. Multi-omics analyses implicated FSCN1 as a functionally relevant downstream candidate associated with La/SSB-dependent phenotypes. Mechanistically, La/SSB depletion was associated with reduced H3K27ac enrichment and diminished TFAP2C occupancy at the FSCN1 promoter, supporting a TFAP2C/FSCN1-linked regulatory framework. Importantly, loss of La/SSB significantly enhanced CDDP responsiveness in the PDO model established in this study and in vivo conditional knockout models. Clinically, elevated La/SSB showed independent prognostic value, whereas TFAP2C and FSCN1 supported a biologically associated regulatory framework linked to aggressive disease features. Collectively, our findings identify La/SSB as a clinically relevant factor associated with HNSCC progression and CDDP responsiveness, and support a TFAP2C/FSCN1-linked regulatory framework that may contribute to malignant phenotypes. Introduction HNSCC represents the most prevalent histological subtype of head and neck cancers, accounting for more than 90% of cases [1]. Notwithstanding ongoing improvements in surgical approaches, radiotherapy, and the addition of immunotherapy, the 5-year OS rate remains below 65% [2–4]. Local recurrence, distant metastasis, and resistance to chemotherapy—particularly to platinum-based regimens—remain major obstacles to successful treatment [5, 6]. The molecular mechanisms underlying HNSCC progression and therapy resistance therefore warrant in-depth investigation to identify new prognostic markers and therapeutic targets. The La antigen, also known as Sjögren syndrome type B antigen (La/SSB or LARP3), is an evolutionarily conserved RNA-binding protein that participates in RNA maturation, stability, and translation [7–9]. Beyond its physiological roles in RNA metabolism, aberrant overexpression of La/SSB has been reported in multiple malignancies, including hepatocellular carcinoma, lung cancer, and breast cancer [10–12]. Elevated La/SSB levels are often associated with enhanced tumor proliferation, invasion, and resistance to genotoxic stress, suggesting that La/SSB may function as an oncogenic factor in cancer biology [13–15]. However, the specific role and regulatory mechanisms of La/SSB in HNSCC remain poorly understood. Previous studies have already implicated La/SSB in the malignant behavior of HNSCC and related squamous cell carcinomas. Heise et al. showed that La/SSB promotes CDDP resistance in HNSCC cells by enhancing translation of the anti-apoptotic factor Bcl2, whereas Sommer et al. demonstrated that La/SSB supports proliferation, migration, and invasion in hypopharyngeal squamous cell carcinoma models [16, 17]. These findings establish La/SSB as a functionally relevant oncogenic RNA-binding protein in squamous malignancies and provide an important foundation for the present study. La/SSB is canonically recognized as a core RNA chaperone for RNA polymerase III transcripts, including pre-tRNAs, 5S rRNA, and U6 snRNA, thereby supporting translational capacity and anabolic metabolism. In cancer, these established functions may cooperate with additional regulatory activities. Building on prior studies, the present work explores whether La/SSB also contributes to malignant progression through downstream chromatin and transcriptional programs in clinically relevant HNSCC models. Recent studies have underscored the importance of RNA-binding proteins (RBPs) as molecular hubs that connect post-transcriptional regulation with promoter-associated chromatin accessibility changes and signal transduction, thereby reprogramming cellular phenotypes during malignant transformation [18, 19]. Whether La/SSB engages in similar regulatory cross-talk to modulate tumor progression in HNSCC has not been systematically examined. In this study, we comprehensively investigated the expression pattern, functional significance, and mechanistic basis of La/SSB in HNSCC using integrated transcriptomic and chromatin accessibility profiling. Through in vitro and in vivo validation, including a patient-derived organoid (PDO) model, cell line-derived xenograft (CDX) model, and conditional La/SSB knockout mouse models, we show that La/SSB is associated with the regulation of tumor proliferation, invasion, and chemoresistance. Collectively, these data suggest that La/SSB may serve as a prognostic biomarker and a context-dependent functional vulnerability in HNSCC. Materials and methods Animal Healthy BALB/c nude mice were sourced from GemPharmatech (Jiangsu, China) and housed at the Animal Experiment Center of Anhui Medical University under conventional laboratory settings. All animal experiments were performed following protocols approved by the Ethics Committee of Anhui Medical University (Anhui, China). For CDX experiments, six-week-old male BALB/c nude mice were randomly assigned to experimental groups (n = 5 per group), and investigators were blinded to group allocation during data collection and analysis. To evaluate the in vivo roles of La/SSB and FSCN1, 4 × 10⁶ cells from the indicated cell lines were resuspended in a volume of 0.2 mL PBS and subcutaneously administered into the axilla to generate xenograft tumors. Tumor size was monitored at 3-day intervals, tumor volume was determined using the formula: volume = (length × width²)/2 (mm³). At the end of the experiment, mice were euthanized, and tumors were harvested, weighed, and photographed, followed by immunohistochemical (IHC) assessment. For metastasis studies, nude mice received tail vein injections of 1 million genetically engineered cells suspended in 100 μL PBS. Eight weeks later, the mice were euthanized, and lung tissues were harvested for further analysis. Metastatic nodules were visualized under a dissecting microscope following hematoxylin and eosin (H&E) staining. For the conditional knockout mice model, La/ssbfl/fl mice were crossed with Krt14Cre/ERT2 mice to generate La/ssbfl/fl; Krt14Cre/ERT2 offspring. All mouse strains were sourced from the Shanghai Model Organisms Center and maintained under specific pathogen-free (SPF) conditions. To establish an HNSCC model, six-week-old La/ssbwt/wt; Krt14Cre/ERT2 mice (designated as La/ssbCtrl) and La/ssbfl/fl; Krt14Cre/ERT2 mice (designated as La/ssbcKO) were administered drinking water supplemented with 4-nitroquinoline 1-oxide (4NQO, 50 μg/mL) for 16 weeks, followed by replacement with normal drinking water to allow tumor progression. For lineage tracing and conditional deletion of La/SSB, tamoxifen was delivered via intraperitoneal injection at a dose of 120 mg/kg every other day for a total of four injections to induce Cre recombinase activity. Additionally, mice received intraperitoneal injections of CDDP (5 mg/kg) or saline once per week for four consecutive weeks. Upon completion of all treatments, mice were sacrificed, and tongue tissues were harvested for downstream analyses. Cell lines and culture conditions HEK-293T cells were obtained from the American Type Culture Collection (ATCC; VA, USA). The TU686 HNSCC cell line was obtained from the BeNa Culture Collection (Beijing, China; catalog number BNCC359450), while TU212 (catalog number HTX2130), human normal oral keratinocytes (NOK; catalog number HTX2992) and FaDu were supplied by Otwo Biotech (Shenzhen, China). The HNSCC cell lines TU177 and LIU-LSC-1 were characterized in previous studies [20]. All cells were maintained in RPMI 1640 medium (Gibco, NY, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, NY, USA) and penicillin–streptomycin (100 U/mL and 100 μg/mL, respectively; Beyotime, Jiangsu, China). Cells were cultured at 37 °C in a humidified incubator with 5% CO₂ and routinely screened for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (Lonza, #LT07-118). Additional details regarding cell sources and culture conditions are provided in Supplementary Table S1. All cell lines were authenticated by STR profiling and routinely tested for mycoplasma contamination prior to use. Sample collection Human HNSCC specimens were obtained from patients treated at the First Affiliated Hospital of Anhui Medical University (Hefei, Anhui) between 2020 and 2025. Histopathological diagnoses were independently verified by a minimum of two experienced pathologists, and informed written consent was obtained from all participants before sample collection. All surgical and experimental procedures involving human tissues were performed in accordance with protocols approved by the Ethics Committee of the First Affiliated Hospital of Anhui Medical University. Detailed clinicopathological characteristics, including patient age, sex, histological grade, TNM classification, lymph node status, and local invasion, are summarized in Supplementary Tables S2 and S3. Clinical information for the patient from whom the PDO model was established is presented in Supplementary Table S4. Antibodies and reagents Detailed information regarding all antibodies utilized in this study is listed in Supplementary Table S5. CDDP was sourced from MedChemExpress (Monmouth Junction, NJ, USA). Puromycin and dimethyl sulfoxide (DMSO) were acquired from Sigma-Aldrich (MO, USA), whereas 4NQO was obtained from Santa Cruz Biotechnology (CA, USA). Quantitative real-time PCR (qRT-PCR) Total RNA was extracted using TRIzol reagent (Invitrogen, CA, USA). RNA quantity and purity were assessed with a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific). For cDNA synthesis, 1 μg of total RNA was reverse-transcribed into first-strand cDNA using the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). qRT-PCR was performed on a LightCycler 96 system (Roche, Switzerland) using SYBR Premix Ex Taq II (TaKaRa, Kyoto, Japan) following the manufacturer’s protocols. Relative expression levels of target mRNAs were determined using the 2−ΔΔCt method, with β-actin serving as the reference gene. All primers were designed and synthesized by Sangon Biotech (Shanghai, China) and are provided in Supplementary Table S6. H&E and IHC Tumor tissues from various treatment groups or organoid models were fixed in formalin, embedded in paraffin, and sectioned for histological examination. After deparaffinization and rehydration, antigen retrieval was performed, followed by incubation with 3% hydrogen peroxide for 1 h to block endogenous peroxidase activity. Sections were then incubated with 3% bovine serum albumin for 1 h and subsequently with primary antibodies at 4 °C overnight. Horseradish peroxidase-conjugated secondary antibodies were applied, and immunoreactivity was visualized using DAB substrate (Beyotime), with hematoxylin serving as a nuclear counterstain. IHC staining was semi-quantitatively evaluated using either H-scores or positive cell percentages, depending on the marker analyzed. For La/SSB, FSCN1, and TFAP2C, staining was assessed using H-scores based on staining intensity and the percentage of positively stained tumor cells. H-scores were calculated as follows: [(percentage of weak staining × 1) + (percentage of moderate staining × 2) + (percentage of strong staining × 3)], resulting in scores ranging from 0 to 300. For Ki-67 and cleaved caspase-3, staining was quantified by calculating the percentage of positively stained tumor cells using the following formula: positive cell percentage (%) = (number of positively stained tumor cells / total number of tumor cells) × 100%. For quantitative analysis of human tissue and CDX tumor samples, each individual specimen or tumor was considered one biological replicate, and three high-power fields were analyzed as technical replicates. Western blotting Total cellular proteins were extracted using RIPA lysis buffer (Beyotime). Protein samples were separated by 10% SDS–polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA). Membranes were blocked with 5% non-fat milk for 1 h and incubated overnight at 4 °C with primary antibodies (1:1000). Following washes, membranes were treated with the appropriate secondary antibodies at room temperature for 1 h. Protein signals were visualized using Pierce™ ECL Western blot Substrate (Thermo Fisher Scientific, MA, USA) and captured with a ChemiScope 6100 imaging system (Clinx, Shanghai, China). Cell viability HNSCC cells were seeded into 96-well plates at 1.5 × 10³ cells per well. Cell viability was assessed at 24, 48, 72, and 96 h using the Cell Counting Kit-8 (CCK-8; Topscience, Shanghai, China). After a 2-h incubation with the CCK-8 reagent at 37 °C, absorbance was recorded at 450 nm to determine the optical density (OD). Colony formation assays Adherent cells were harvested and counted prior to seeding. Approximately 1000 cells were plated per well in 6-cm culture dishes in triplicate and allowed to grow for 14–16 days. After incubation, the colonies were washed with PBS, fixed in 4% paraformaldehyde, and stained with 0.5% crystal violet (Beyotime, Jiangsu, China). Excess dye was gently washed away with water. Only colonies comprising more than 50 cells were counted and included in subsequent analyses. EdU staining assays For EdU incorporation assays, 4 × 10⁴ cells were plated in each well of 24-well plates and treated with 50 μM EdU for 2 h at 37 °C. Following fixation and permeabilization, EdU labeling was performed using the Cell-Light EdU Apollo488 Kit (RiboBio, Guangzhou, China) according to the manufacturer’s protocol. Images were acquired using an LSM880 + 225 Airyscan confocal microscope (Carl Zeiss). The proliferation rate was calculated as the proportion of EdU-positive cells relative to DAPI-stained nuclei. Cell migration and invasion assays Transwell assays were conducted to evaluate cell migration and invasion. For invasion experiments, the upper surface of the Transwell inserts was coated with 40 μL of Matrigel (Corning, NY, USA). A total of 2 × 10⁴ cells in 200 μL of serum-free medium were added to the upper chamber, while the lower chamber was filled with medium containing 20% FBS. After 24 h of incubation at 37 °C, cells on the lower side of the membrane were fixed with 4% paraformaldehyde, stained with 0.1% crystal violet, and quantified under a microscope. Cell apoptosis analysis Cell apoptosis was evaluated using the Annexin V-APC/PI Apoptosis Detection Kit (Keygen, Jiangsu, China) according to the manufacturer’s instructions. In brief, 3 × 10⁵ adherent cells were harvested with EDTA-free trypsin and washed twice with PBS. Cells were resuspended in 500 μL Binding Buffer and incubated with 5 μL Annexin V-APC and 5 μL propidium iodide (PI) in the dark for 10 min. The percentage of apoptotic cells was determined by flow cytometry (Beckman Coulter, CA, USA). Establishment and culture of HNSCC organoids HNSCC organoids were generated and cultured with minor modifications to previously reported protocols. Fresh HNSCC tumor specimens were washed three times with ice-cold PBS (5 min per wash) and cut into 1–3 mm³ pieces on ice. The tissue fragments were digested with trypsin (Sigma-Aldrich) for about 30 minutes under optimized conditions to preserve organoid viability. Once the suspension became turbid, it was passed through a 100-μm cell strainer and centrifuged at 200 × g for 5 min to collect cell clusters. The collected cell clusters were washed three times with PBS to remove residual enzymes and then embedded in Matrigel (Corning). After the Matrigel had solidified, HNSCC organoid culture medium (BioGenous, Jiangsu, China) was added, and cultures were maintained at 37 °C in a CO₂ incubator, with medium refreshed every 3–5 days. For lentiviral transduction, HNSCC organoids were first dissociated into small cell clusters using a pipette. The clusters were collected by centrifugation at 200 × g for 5 min at 4 °C and resuspended in culture medium (BioGenous) containing the designated lentiviral particles. The suspension was subjected to spin infection at 700 × g for 90 min at 25 °C, followed by incubation at 37 °C for 4 h. After a brief centrifugation at 300 × g for 5 min, the cell clusters were re-embedded in Matrigel. Organoid morphology was imaged, and diameters were measured using image analysis software. Functional assays were performed using a patient-derived HNSCC organoid model established in this study. Organoids or wells represent technical replicates and not independent biological replicates. Immunofluorescence (IF) assay For IF studies, cells were fixed with 4% formaldehyde, permeabilized using 0.5% Triton X-100 (Sigma-Aldrich), and blocked with Immunol Staining Blocking Buffer (Beyotime). Cells were incubated overnight with primary antibodies and subsequently treated with fluorophore-conjugated secondary antibodies (Cell Signaling Technology, MA, USA) for 1 h. Finally, cells were mounted using ProLong Gold Antifade Mountant containing DAPI (Thermo Fisher Scientific) before imaging. For multiplex IF analysis of the PDO model established in this study and orthotopic tongue tumor tissues, sections were stained with antibodies against La/SSB, Ki-67, and cleaved caspase-3. Immunoreactivity was detected using FITC- or Cy3-conjugated secondary antibodies (Cell Signaling Technology, MA, USA), followed by nuclear counterstaining with DAPI (Beyotime). To assess Ki-67 and cleaved caspase-3 expression, the percentage of marker-positive cells was calculated as follows: positive cell percentage (%) = (number of positively stained tumor cells / total number of tumor cells) × 100%. For quantitative analysis of orthotopic tongue tumor tissues, each individual tumor was considered one biological replicate, and three high-power fields were analyzed as technical replicates. For PDO fluorescence analysis, this study used a single PDO line; therefore, statistical analyses were not performed across independent donors, and n represents technical replicates within this single PDO line. Lentivirus infection All lentiviral constructs were purchased from GenePharma (Shanghai, China), including LV4 plasmids encoding La/SSB, FSCN1, and TFAP2C cDNAs, as well as an empty vector control. In addition, the LV-2 N lentiviral shRNA vector was employed to knock down La/SSB, FSCN1, and TFAP2C, alongside a scrambled shRNA control (shSc). Target sequences are provided in Supplementary Table S7. Lentiviral production and the establishment of stable cell lines were performed as described previously [21]. RNA sequencing (RNA-seq) RNA-seq was performed by LC Sciences (Hangzhou, China). Briefly, total RNA was isolated from three independent biological replicates of shLa/SSB FaDu cells and their corresponding control cells. cDNA was converted to double-stranded DNA, followed by PCR amplification and 2 × 150 bp paired-end sequencing (PE150) on an Illumina Novaseq™ 6000. The resulting reads were aligned to the human reference genome (hg38) and assembled using StringTie with default parameters to generate normalized expression values (FPKM). Differential expression analysis was performed using the edgeR package in R. Raw read counts were normalized to library size using the trimmed mean of M-values (TMM) method. Common, trended, and tagwise dispersions were sequentially estimated using the edgeR pipeline, and empirical Bayes moderation was applied to shrink the dispersions toward the trended dispersion prior to differential expression testing using the exact test. Genes with adjusted P-values (FDR) < 0.05 and |log₂FC | ≥ 1 were considered significantly differentially expressed. Sequencing depth, mapping rate, and genomic distribution of mapped reads were assessed to ensure data reliability. Detailed sequencing quality control metrics, including read statistics, mapping rates, and gene body coverage, are summarized in Supplementary Table S8 (Sheets 2–5). Dispersion estimates are provided in Supplementary Table S8, Sheet 6. Assay for transposase accessible chromatin with high-throughput sequencing (ATAC-seq) ATAC-seq was carried out with support from Igenebook (Wuhan, China). All experiments were performed with three independent biological replicates (n = 3). Nuclei were isolated from 50,000 cells, washed, and resuspended in nuclear lysis buffer. Chromatin accessibility was assessed via transposition using Tn5 transposase, which fragments and tags open chromatin regions. The transposed DNA was purified using the Qiagen MinElute PCR Purification Kit (Qiagen, Hilden, Germany) and amplified by PCR with unique barcodes. PCR products were further cleaned to remove residual primers and adapter dimers, and library quality and concentration were checked using an Agilent Bioanalyzer. Sequencing was performed on an Illumina NovaSeq™ platform to obtain 150 bp paired-end reads. Transcription start sites (TSS) enrichment scores ranged from 8.5 to 20.5 across all samples, with consistent, sharp enrichment peaks centered at TSS, confirming the high quality of the chromatin accessibility libraries. Raw reads were subjected to strict quality control, including removal of adapters, low-quality reads, and mitochondrial reads. Clean reads were aligned to the human reference genome (hg38) using Bowtie2. Duplicated reads were marked and removed using Picard. Raw sequencing data were processed using a standard bioinformatics pipeline, including alignment, peak calling, and differential chromatin accessibility analysis. Peak calling was performed using MACS2 (v2.1.2) with parameters: --nomodel --shift -100 --extsize 200 --qvalue 0.05. Irreproducible Discovery Rate (IDR) analysis was performed between biological replicates to ensure high reproducibility, and only high-confidence peaks with IDR < 0.05 were retained for downstream analysis. The FRiP score (Fraction of Reads in Peaks) was calculated to evaluate data quality. Differential chromatin accessibility analysis between groups was conducted using the DiffBind package. For candidate gene prioritization, peaks with nominal P < 0.05 were considered for exploratory prioritization, given the limited statistical power at specific loci. ATAC-seq data met standard quality metrics, with high reproducibility across biological replicates (Supplementary Table S9, Sheets 2–4). Reporter constructs and luciferase reporter assay A 190-bp fragment of the human FSCN1 gene (-1339/-1139), which includes the TFAP2C-binding site, was amplified from human genomic DNA by PCR. The resulting PCR product was inserted into the pGL4.23[luc2/minP] luciferase reporter vector (Promega) using homologous recombination. The primers used for amplification are listed below: forward, 5’-TAACTGGCCGGTACCGTTCTGGGGCTCAAGGCCCT-3’; reverse, 5’-CTTGATATCCTCGAGGGCCGGGCACTGAGATAACT-3’. A mutant reporter plasmid (pFSCN1mut-Luc) was generated by altering the TFAP2C-binding site using the Q5 Site-Directed Mutagenesis Kit (NEB, MA, USA) with the following primers: forward, 5’-GGGCTAACACAGGCTCGGACCAGC-3’; reverse, 5’-CATTTAATCCCAGCCAGGGGCTTTC-3’. HEK-293T, FaDu, and TU177 cells were seeded in 24-well plates and co-transfected with 200 ng of either FSCN1wt-Luc or pFSCN1mut-Luc, 200 ng of pcDNA3.1-TFAP2C or empty pcDNA3.1 vector, and 10 ng of the internal control plasmid pRL-TK. Dual luciferase reporter assays were performed in HEK-293T, FaDu, and TU177 cells. Luciferase activity was determined using the Dual-Luciferase Reporter Assay System (Promega), and firefly luciferase signals were normalized to Renilla luciferase. Chromatin immunoprecipitation (ChIP) The binding of TFAP2C to the FSCN1 promoter was assessed by ChIP using a TFAP2C-specific antibody. H3K27ac ChIP-qRT-PCR was performed in parallel using the same protocol with an H3K27ac-specific antibody. ChIP assays were carried out according to the protocol provided with the SimpleChIP Plus Enzymatic Chromatin IP Kit (Cell Signaling Technology, MA, USA), with chromatin enzymatically fragmented to an average size of 200–500 bp prior to immunoprecipitation. Primers used for PCR and qRT-PCR to amplify the predicted TFAP2C-binding sites within the human FSCN1 locus are listed in Supplementary Table S10. Bioinformatics analysis RNA-seq data and corresponding clinical information for patients with HNSCC were obtained from The Cancer Genome Atlas (TCGA). OS analyses were initially performed using Kaplan–Meier curves and the log-rank test, with patients stratified into high- and low-expression groups according to the median expression levels of TFAP2C, La/SSB, or FSCN1. To further assess whether these genes were independently associated with patient prognosis, univariable and multivariable Cox proportional hazards regression analyses were performed. Multivariable models were adjusted for relevant clinicopathological covariates, including age, sex, clinical stage, HPV status, smoking history, alcohol history, treatment-related variables, and, where available, neck lymph node dissection status. Samples with missing values in variables included in a given model were excluded from that analysis. The proportional hazards assumption was assessed using Schoenfeld residual-based tests. Gene expression correlations were evaluated using Spearman’s correlation analysis with further stratification by HPV status, and receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic performance of these genes. Statistical analysis All statistical analyses were performed using GraphPad Prism. Differences between two groups were evaluated using an unpaired two-sided Student’s t-test, except for paired comparisons of matched samples, for which a paired two-sided Student’s t-test was used. Comparisons among more than two groups were performed using one-way analysis of variance (ANOVA), followed by appropriate post hoc tests. Survival, correlation, and ROC analyses were performed as described in the corresponding sections or figure legends. For in vitro experiments, data represent at least three independent biological replicates unless otherwise indicated. PDO data were obtained from a single PDO line. Organoids or wells represent technical replicates and not independent biological replicates. The number of animals used in in vivo experiments is specified in each figure legend. Data are presented as mean ± standard deviation (SD), and “n” denotes independent biological replicates as defined in each figure legend. A P < 0.05 was considered statistically significant. ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001, ****P < 0.0001. Results La/SSB is upregulated in HNSCC and is associated with poor patient prognosis Pan-cancer analysis of TCGA data indicated that La/SSB expression was markedly increased in various tumor types, including HNSCC (Fig. S1A). To clarify its clinical significance, La/SSB expression was compared between tumor and adjacent non-malignant tissues (ANM) using TCGA, GSE127165, and GSE178537 datasets. All datasets consistently demonstrated marked upregulation of La/SSB in HNSCC tissues (Fig. 1A–C).Fig. 1La/SSB is highly expressed in HNSCC and correlates with poor prognosis.La/SSB expression in ANM samples and tumor tissues was analyzed using the TCGA-HNSCC (A), GSE127165 (B), and GSE178537 (C) datasets. Kaplan–Meier curves depicting OS (D) and DSS (E) of HNSCC patients from the TCGA cohort stratified by La/SSB expression. F Western blot analysis of 12 paired ANM samples and HNSCC tissues. G, H H-score quantification of IHC staining in 60 paired ANM and HNSCC tissues (G) with representative images shown in (H). Scale bars: 200 μm (low magnification), 50 μm (high magnification). I Kaplan–Meier analysis of OS in 60 HNSCC patients based on median H-score of La/SSB IHC staining, dividing patients into high (n = 30) and low (n = 30) expression groups. J La/SSB mRNA and protein levels in NOK and HNSCC cell lines (TU177, FaDu, TU686, LIU-LSC-1, TU212) were assessed by qRT-PCR (n = 3 independent biological replicates) and Western blot. K Representative IF images of La/SSB in NOK and HNSCC cell lines. Scale bar: 20 μm. Unpaired two-tailed Student’s t-test (A, C and right panel of G). Paired two-tailed Student’s t-test (B and left panel of G). Survival curves were compared using the log-rank test (D, E and I). One-way ANOVA followed by Dunnett’s multiple-comparisons test was used, with NOK as the reference group (J). Data are presented as mean ± SD where applicable. *P < 0.05 ***P < 0.001. La/SSB is highly expressed in HNSCC and correlates with poor prognosis. La/SSB expression in ANM samples and tumor tissues was analyzed using the TCGA-HNSCC (A), GSE127165 (B), and GSE178537 (C) datasets. Kaplan–Meier curves depicting OS (D) and DSS (E) of HNSCC patients from the TCGA cohort stratified by La/SSB expression. F Western blot analysis of 12 paired ANM samples and HNSCC tissues. G, H H-score quantification of IHC staining in 60 paired ANM and HNSCC tissues (G) with representative images shown in (H). Scale bars: 200 μm (low magnification), 50 μm (high magnification). I Kaplan–Meier analysis of OS in 60 HNSCC patients based on median H-score of La/SSB IHC staining, dividing patients into high (n = 30) and low (n = 30) expression groups. J La/SSB mRNA and protein levels in NOK and HNSCC cell lines (TU177, FaDu, TU686, LIU-LSC-1, TU212) were assessed by qRT-PCR (n = 3 independent biological replicates) and Western blot. K Representative IF images of La/SSB in NOK and HNSCC cell lines. Scale bar: 20 μm. Unpaired two-tailed Student’s t-test (A, C and right panel of G). Paired two-tailed Student’s t-test (B and left panel of G). Survival curves were compared using the log-rank test (D, E and I). One-way ANOVA followed by Dunnett’s multiple-comparisons test was used, with NOK as the reference group (J). Data are presented as mean ± SD where applicable. *P < 0.05 ***P < 0.001. Kaplan–Meier survival analysis demonstrated that patients with higher La/SSB expression had shorter overall survival (OS) and disease-specific survival (DSS) (Fig. 1D, E; Tables 1, 2). Western blot analysis of 12 paired HNSCC and ANM samples revealed that La/SSB protein levels were elevated in the majority of tumor tissues (Fig. 1F). IHC staining of an expanded cohort of 60 HNSCC specimens further verified this finding, with significantly higher H-scores observed in tumor tissues compared with adjacent mucosa. Importantly, La/SSB levels were higher in tumors with advanced T stage (T3/T4 compared with T1/T2; Fig. 1G, H) and were associated with reduced OS (Fig. 1I).Table 1Univariate and multivariate Cox regression analyses of the correlation between clinical characteristics with OS.Univariate analysisMultivariate analysisCharacteristicsTotal(N)Hazard ratio (95% CI)P valueHazard ratio (95% CI)P valueAge478<= 60237ReferenceReference> 602411.088 (0.770–1.538)0.6321.134 (0.794–1.619)0.489Gender478Female123ReferenceReferenceMale3550.968 (0.652–1.439)0.8740.942 (0.628–1.415)0.775Histologic grade463G1&G2347ReferenceReferenceG3&G41161.055 (0.715–1.557)0.7880.986 (0.666–1.460)0.944Clinical stage464Stage I&Stage II107ReferenceReferenceStage III&Stage IV3571.161 (0.759–1.775)0.4921.091 (0.705–1.687)0.695La/SSB478Low239ReferenceReferenceHigh2391.812 (1.270–2.587)0.0011.924 (1.337–2.771)< 0.001Table 2Univariate and multivariate Cox regression analyses of the correlation among the clinical characteristics with DSS.Univariate analysisMultivariate analysisCharacteristicsTotal(N)Hazard ratio (95% CI)P valueHazard ratio (95% CI)P valueAge503<= 60247ReferenceReference> 602561.262 (0.964–1.653)0.0901.349 (1.015–1.791)0.039Gender503Female134ReferenceReferenceMale3690.760 (0.571–1.012)0.0610.772 (0.571–1.043)0.092Histologic grade483G1&G2362ReferenceReferenceG3&G41210.942 (0.690–1.286)0.7060.894 (0.653–1.225)0.487Clinical stage489Stage I&Stage II114ReferenceReferenceStage III&Stage IV3751.226 (0.885–1.700)0.2211.191 (0.849–1.671)0.312La/SSB503Low251ReferenceReferenceHigh2521.563 (1.193–2.049)0.0011.717 (1.296–2.276)<0.001 Table 1Univariate and multivariate Cox regression analyses of the correlation between clinical characteristics with OS.Univariate analysisMultivariate analysisCharacteristicsTotal(N)Hazard ratio (95% CI)P valueHazard ratio (95% CI)P valueAge478<= 60237ReferenceReference> 602411.088 (0.770–1.538)0.6321.134 (0.794–1.619)0.489Gender478Female123ReferenceReferenceMale3550.968 (0.652–1.439)0.8740.942 (0.628–1.415)0.775Histologic grade463G1&G2347ReferenceReferenceG3&G41161.055 (0.715–1.557)0.7880.986 (0.666–1.460)0.944Clinical stage464Stage I&Stage II107ReferenceReferenceStage III&Stage IV3571.161 (0.759–1.775)0.4921.091 (0.705–1.687)0.695La/SSB478Low239ReferenceReferenceHigh2391.812 (1.270–2.587)0.0011.924 (1.337–2.771)< 0.001 Univariate and multivariate Cox regression analyses of the correlation between clinical characteristics with OS. Table 2Univariate and multivariate Cox regression analyses of the correlation among the clinical characteristics with DSS.Univariate analysisMultivariate analysisCharacteristicsTotal(N)Hazard ratio (95% CI)P valueHazard ratio (95% CI)P valueAge503<= 60247ReferenceReference> 602561.262 (0.964–1.653)0.0901.349 (1.015–1.791)0.039Gender503Female134ReferenceReferenceMale3690.760 (0.571–1.012)0.0610.772 (0.571–1.043)0.092Histologic grade483G1&G2362ReferenceReferenceG3&G41210.942 (0.690–1.286)0.7060.894 (0.653–1.225)0.487Clinical stage489Stage I&Stage II114ReferenceReferenceStage III&Stage IV3751.226 (0.885–1.700)0.2211.191 (0.849–1.671)0.312La/SSB503Low251ReferenceReferenceHigh2521.563 (1.193–2.049)0.0011.717 (1.296–2.276)<0.001 Univariate and multivariate Cox regression analyses of the correlation among the clinical characteristics with DSS. At the cellular level, quantitative RT-PCR and Western blot revealed substantially higher La/SSB expression in HNSCC cell lines (FaDu, TU177, TU686, TU212, LIU-LSC-1) compared with NOK (Fig. 1J). IF imaging supported predominant nuclear localization of La/SSB in HNSCC cells (Fig. 1K). Taken together, these findings support La/SSB as a tumor-associated biomarker linked to HNSCC progression and poor clinical outcomes. La/SSB enhances proliferation, migration, and apoptosis resistance of HNSCC cells in vitro To investigate the functional consequences of La/SSB dysregulation, loss- and gain-of-function experiments were performed. Stable knockdown of La/SSB was achieved in FaDu cells using shRNAs (shLa/SSB#1 and shLa/SSB#2), whereas TU177 cells were engineered to overexpress La/SSB. Western blot and qRT-PCR analyses supported the effective modulation of La/SSB expression (Fig. 2A, B, Fig. S2A–B).Fig. 2La/SSB enhances tumorigenic capacity of HNSCC cells in vitro.FaDu cells were transduced with lentiviruses expressing shRNAs targeting La/SSB (shLa/SSB#1 and shLa/SSB#2) or a scrambled control sequence (shSc) (A), whereas TU177 cells were transduced with either a control vector or lentiviruses encoding La/SSB (B); La/SSB protein levels were assessed by Western blot. C, D Cell proliferation was evaluated via EdU incorporation assays. Scale bars: 100 μm. E Schematic representation illustrates the enzymatic digestion and initial culture procedure for HNSCC organoids. F Representative histological and IHC images of CK13, p63, and La/SSB staining in HNSCC tissues and matched organoids are shown. Scale bars: 40 μm (tissues), 100 μm (organoids). G La/SSB protein expression in organoids was supported by Western blot. H, I Representative images display organoid diameters and Ki-67 IF intensity following La/SSB knockdown or overexpression. Scale bars: 400 μm (low magnification), 100 μm (high magnification), 40 μm (IF); PDO data were obtained from a single PDO line. Organoids and microscopic fields or wells analyzed within this PDO line were considered technical replicates, not independent biological replicates. Organoid diameter was quantified from 30 organoids (n = 30 organoids, technical replicates), and Ki-67-positive cells were quantified from five microscopic fields (n = 5 fields, technical replicates). J, K Transwell assays were performed to assess migration and invasion in La/SSB-knockdown FaDu cells and La/SSB-overexpressing TU177 cells. Scale bars: 100 μm. n = 3 independent biological replicates (C, D, J and K). Unpaired two-tailed Student’s t-test (C and D, H–K). Data are presented as mean ± SD where applicable. **P < 0.01, ***P < 0.001, ****P < 0.0001. La/SSB enhances tumorigenic capacity of HNSCC cells in vitro. FaDu cells were transduced with lentiviruses expressing shRNAs targeting La/SSB (shLa/SSB#1 and shLa/SSB#2) or a scrambled control sequence (shSc) (A), whereas TU177 cells were transduced with either a control vector or lentiviruses encoding La/SSB (B); La/SSB protein levels were assessed by Western blot. C, D Cell proliferation was evaluated via EdU incorporation assays. Scale bars: 100 μm. E Schematic representation illustrates the enzymatic digestion and initial culture procedure for HNSCC organoids. F Representative histological and IHC images of CK13, p63, and La/SSB staining in HNSCC tissues and matched organoids are shown. Scale bars: 40 μm (tissues), 100 μm (organoids). G La/SSB protein expression in organoids was supported by Western blot. H, I Representative images display organoid diameters and Ki-67 IF intensity following La/SSB knockdown or overexpression. Scale bars: 400 μm (low magnification), 100 μm (high magnification), 40 μm (IF); PDO data were obtained from a single PDO line. Organoids and microscopic fields or wells analyzed within this PDO line were considered technical replicates, not independent biological replicates. Organoid diameter was quantified from 30 organoids (n = 30 organoids, technical replicates), and Ki-67-positive cells were quantified from five microscopic fields (n = 5 fields, technical replicates). J, K Transwell assays were performed to assess migration and invasion in La/SSB-knockdown FaDu cells and La/SSB-overexpressing TU177 cells. Scale bars: 100 μm. n = 3 independent biological replicates (C, D, J and K). Unpaired two-tailed Student’s t-test (C and D, H–K). Data are presented as mean ± SD where applicable. **P < 0.01, ***P < 0.001, ****P < 0.0001. CCK-8, colony formation, and EdU assays demonstrated that depletion of La/SSB substantially inhibited the proliferation of HNSCC cells, while its overexpression significantly enhanced growth (Fig. 2C, D, Fig. S2C–E). Given the ability of PDOs to preserve key tumor features, we next evaluated La/SSB function in a single PDO line established in this study. La/SSB overexpression promoted organoid growth, as reflected by increased organoid diameter and enhanced Ki-67 positivity, whereas La/SSB depletion suppressed organoid growth and reduced Ki-67 positivity and organoid diameter (Fig. 2E–I). Transwell assays showed that silencing La/SSB markedly impaired the migratory and invasive abilities of FaDu cells, whereas overexpression enhanced these phenotypes in TU177 cells (Fig. 2J, K). Flow cytometric analysis further showed that La/SSB silencing increased apoptotic cell populations, while its overexpression conferred apoptosis resistance (Fig. S2F–G). Together, these findings support a functional role for La/SSB in promoting HNSCC cell proliferation, migration, and apoptosis resistance in vitro. La/SSB promotes tumor growth and lung colonization in vivo To investigate the tumor-promoting function of La/SSB in vivo, CDX models were generated in nude mice using FaDu cells with stable La/SSB knockdown or TU177 cells overexpressing La/SSB. Tumor growth was monitored over four weeks. Silencing La/SSB significantly delayed tumor growth and reduced tumor volume and weight, whereas La/SSB overexpression markedly accelerated tumor progression (Fig. 3A–D; Fig. S3A–D). IHC analysis revealed lower Ki-67 and higher cleaved caspase-3 levels in La/SSB-deficient tumors, whereas the opposite pattern was observed in La/SSB-overexpressing xenografts (Fig. 3E–H; Fig. S3E–H).Fig. 3La/SSB enhances tumorigenic capacity of HNSCC cells in vivo.A–H FaDu cells with the indicated modifications were subcutaneously injected into mice to monitor tumor growth, with n = 5 mice per group. Representative images of the tumors are shown (A), along with tumor weights (B), tumor volumes (C), and body weights of the mice over time (D). IHC staining of xenograft tissues for La/SSB, Ki-67, and cleaved caspase-3 is presented in (E), and the corresponding quantitative analyses are shown in (F–H). Scale bar: 50 μm. I, J FaDu cells with the indicated modifications were injected into mice via the tail vein to evaluate lung metastasis, with n = 5 mice per group. Representative images of lungs and H&E-stained lung sections are shown in (I), and quantification of lung metastatic nodules and lung weights is shown in (J). K, L TU177 cells transduced with control vector or La/SSB-overexpressing lentivirus were injected into mice via the tail vein to evaluate lung metastasis, with n = 5 mice per group. Representative images of lungs and H&E-stained lung sections are shown in (K), and quantification of lung metastatic nodules and lung weights is shown in (L). Red arrowheads indicate metastatic nodules. Scale bars: 1 cm (gross lung images), 2 mm (H&E-stained lung sections). Unpaired two-tailed Student’s t-test (B and C, F–H, J and L). Data are presented as mean ± SD where applicable. **P < 0.01, ***P < 0.001, ****P < 0.0001. La/SSB enhances tumorigenic capacity of HNSCC cells in vivo. A–H FaDu cells with the indicated modifications were subcutaneously injected into mice to monitor tumor growth, with n = 5 mice per group. Representative images of the tumors are shown (A), along with tumor weights (B), tumor volumes (C), and body weights of the mice over time (D). IHC staining of xenograft tissues for La/SSB, Ki-67, and cleaved caspase-3 is presented in (E), and the corresponding quantitative analyses are shown in (F–H). Scale bar: 50 μm. I, J FaDu cells with the indicated modifications were injected into mice via the tail vein to evaluate lung metastasis, with n = 5 mice per group. Representative images of lungs and H&E-stained lung sections are shown in (I), and quantification of lung metastatic nodules and lung weights is shown in (J). K, L TU177 cells transduced with control vector or La/SSB-overexpressing lentivirus were injected into mice via the tail vein to evaluate lung metastasis, with n = 5 mice per group. Representative images of lungs and H&E-stained lung sections are shown in (K), and quantification of lung metastatic nodules and lung weights is shown in (L). Red arrowheads indicate metastatic nodules. Scale bars: 1 cm (gross lung images), 2 mm (H&E-stained lung sections). Unpaired two-tailed Student’s t-test (B and C, F–H, J and L). Data are presented as mean ± SD where applicable. **P < 0.01, ***P < 0.001, ****P < 0.0001. Furthermore, tail vein injection assays demonstrated that La/SSB knockdown dramatically decreased the number of pulmonary metastatic nodules, whereas La/SSB overexpression enhanced lung colonization (Fig. 3I–L). These results support a role for La/SSB in promoting HNSCC tumor growth and lung colonization in vivo. Integrated transcriptomic and epigenomic profiling identifies FSCN1 as a downstream effector of La/SSB To explore the molecular mechanisms underlying La/SSB-associated tumor-promoting effects, RNA-seq was performed in FaDu cells after La/SSB knockdown. Pearson correlation and PCA validated RNA-seq reliability, showing high replicate reproducibility (R > 0.99) and clear separation between shSc and shLa/SSB groups (Fig. S4A–B). We identified 2,085 DEGs (|log₂FC | > 1, FDR ≤ 0.05), comprising 1,174 downregulated and 911 upregulated transcripts (Fig. 4A; Supplementary Tables S8, Sheet 1).Fig. 4Integrated transcriptomic and epigenomic profiling identifies FSCN1 as a downstream effector of La/SSB.A RNA-seq analysis of shLa/SSB#1 FaDu cells and corresponding control cells. The volcano plot shows differentially expressed genes defined by |log₂FC | > 1 and FDR < 0.05. n = 3 independent biological replicates. B Schematic workflow for screening and identifying candidate downstream targets of La/SSB. Three independent datasets (RNA-seq, TCGA, and CPTAC) were intersected to identify 33 overlapping candidates. Univariate Cox regression analysis (HR > 1, P < 0.05) further prioritized 13 prognosis-associated genes as key downstream targets. C ATAC-seq analysis of shLa/SSB#1 FaDu cells and corresponding control cells. Heatmaps and enrichment profiles show normalized ATAC-seq signal densities centered on transcription start sites (TSSs) and extending ±2 kb. n = 3 independent biological replicates. D Fold changes and P values of promoter-associated ATAC-seq peaks for the 13 prognostic candidate genes. Among these candidates, FSCN1 showed a detectable (exploratory) reduction in promoter accessibility. E IGV visualization of ATAC-seq signals at the FSCN1 locus, showing reduced ATAC-seq signals at the FSCN1 promoter after La/SSB knockdown. F, G FSCN1 expression was examined by qRT-PCR and Western blotting in La/SSB-knockdown FaDu cells and La/SSB-overexpressing TU177 cells, together with their respective control cells. H H-score quantification of FSCN1 immunostaining. I Kaplan–Meier analysis of OS in 60 patients with HNSCC stratified by FSCN1 protein expression. Patients were divided into high-expression (n = 30) and low-expression (n = 30) groups according to the median IHC H-score, and were compared using the log-rank test. Unpaired two-tailed Student’s t-test (G and right panel of H). Paired two-tailed Student’s t-test (left panel of H). Data are presented as mean ± SD where applicable. *P < 0.05, ***P < 0.001, ****P < 0.0001. Integrated transcriptomic and epigenomic profiling identifies FSCN1 as a downstream effector of La/SSB. A RNA-seq analysis of shLa/SSB#1 FaDu cells and corresponding control cells. The volcano plot shows differentially expressed genes defined by |log₂FC | > 1 and FDR < 0.05. n = 3 independent biological replicates. B Schematic workflow for screening and identifying candidate downstream targets of La/SSB. Three independent datasets (RNA-seq, TCGA, and CPTAC) were intersected to identify 33 overlapping candidates. Univariate Cox regression analysis (HR > 1, P < 0.05) further prioritized 13 prognosis-associated genes as key downstream targets. C ATAC-seq analysis of shLa/SSB#1 FaDu cells and corresponding control cells. Heatmaps and enrichment profiles show normalized ATAC-seq signal densities centered on transcription start sites (TSSs) and extending ±2 kb. n = 3 independent biological replicates. D Fold changes and P values of promoter-associated ATAC-seq peaks for the 13 prognostic candidate genes. Among these candidates, FSCN1 showed a detectable (exploratory) reduction in promoter accessibility. E IGV visualization of ATAC-seq signals at the FSCN1 locus, showing reduced ATAC-seq signals at the FSCN1 promoter after La/SSB knockdown. F, G FSCN1 expression was examined by qRT-PCR and Western blotting in La/SSB-knockdown FaDu cells and La/SSB-overexpressing TU177 cells, together with their respective control cells. H H-score quantification of FSCN1 immunostaining. I Kaplan–Meier analysis of OS in 60 patients with HNSCC stratified by FSCN1 protein expression. Patients were divided into high-expression (n = 30) and low-expression (n = 30) groups according to the median IHC H-score, and were compared using the log-rank test. Unpaired two-tailed Student’s t-test (G and right panel of H). Paired two-tailed Student’s t-test (left panel of H). Data are presented as mean ± SD where applicable. *P < 0.05, ***P < 0.001, ****P < 0.0001. To identify high-confidence downstream targets of La/SSB, we performed a multi-step integrative screening workflow (Fig. 4B). First, we intersected three independent datasets: (1) downregulated genes from our RNA-seq (log₂FC < −1, FDR < 0.05); (2) upregulated genes from the TCGA-HNSCC dataset (log₂FC > 1, FDR < 0.05); and (3) upregulated genes from the CPTAC-HNSCC dataset (log₂FC > 0.585, FDR < 0.05). This intersection yielded 33 overlapping candidate genes. Next, we filtered these candidates using univariate Cox regression analysis in the TCGA-HNSCC d3ataset (HR > 1, P < 0.05), identifying a final list of 13 prognostic genes (Supplementary Table S11). To further screen the downstream target genes of La/SSB, we performed ATAC-seq in La/SSB-knockdown FaDu cells. ATAC-seq revealed substantial changes in chromatin accessibility after La/SSB depletion (Fig. 4C; Supplementary Tables S9, Sheet 1). At the promoter level, FSCN1 was prioritized as an exploratory candidate based on a detectable reduction in promoter accessibility after La/SSB knockdown (fold change = −1.41, P = 0.00137), whereas other candidate genes showed either non-significant changes or undetectable promoter-associated peaks (Fig. 4D). Integrative Genomics Viewer (IGV) analysis showed reduced ATAC-seq signal at the FSCN1 promoter locus in La/SSB-knockdown cells across all three biological replicates (Fig. 4E), consistent with decreased chromatin accessibility at this region. FSCN1 mRNA expression was markedly elevated in HNSCC tissues compared with ANM samples across TCGA datasets (Fig. S4C). Consistent with these findings, FSCN1 expression was most strongly associated with poor patient survival (P < 0.01; Fig. S4D). Correspondingly, in FaDu cells with La/SSB silencing, FSCN1 mRNA and protein levels were decreased, whereas in TU177 cells overexpressing La/SSB, FSCN1 expression was elevated (Fig. 4F, G, Fig. S4E). IHC staining of clinical samples supported co-upregulation of La/SSB and FSCN1. Higher FSCN1 expression was correlated with advanced T stage and reduced OS (Fig. 4H, I). Collectively, these results identify FSCN1 as a functionally relevant downstream effector candidate of La/SSB in HNSCC. FSCN1 partially recapitulates and may contribute to the oncogenic functions of La/SSB in HNSCC To evaluate whether FSCN1 independently exhibits oncogenic activity similar to that of La/SSB, we first generated HNSCC cell lines with stable FSCN1 knockdown or overexpression (Fig. S5A). In FaDu cells, knockdown of FSCN1 significantly suppressed cell proliferation, colony formation, and DNA synthesis, as shown by CCK-8, colony formation, and EdU assays, whereas overexpression of FSCN1 in TU177 cells led to enhanced proliferation and DNA synthesis (Fig. S5B–E). In the PDO model, FSCN1 depletion significantly reduced organoid size and growth rate, while FSCN1 overexpression enhanced organoid expansion and Ki-67 positivity (Fig. S5F–G). Transwell assays demonstrated that silencing FSCN1 reduced cell migration and invasion, while FSCN1 overexpression enhanced these properties (Fig. S5H–I). Flow-cytometric analysis revealed that FSCN1 silencing increased apoptosis, whereas FSCN1 overexpression conferred apoptosis resistance (Fig. S5J–K). These results indicate that FSCN1 phenocopies the tumor-promoting roles of La/SSB in vitro. In line with the in vitro results, xenograft studies showed that FSCN1 depletion significantly decreased tumor size and weight, whereas FSCN1 overexpression promoted tumor growth (Fig. S6A–D and Fig. S6I–L). IHC staining of xenograft tissues supported that FSCN1-deficient tumors exhibited decreased Ki-67 and increased cleaved caspase-3 levels, while FSCN1-overexpressing tumors showed the opposite pattern (Fig. S6E–H and Fig. S6M–P). Together, these data indicate that FSCN1 recapitulates key La/SSB-associated oncogenic phenotypes both in vitro and in vivo. To further determine whether FSCN1 functionally may contribute to La/SSB-associated malignant phenotypes, rescue experiments were performed by re-expressing FSCN1 in La/SSB-knockdown FaDu cells (Fig. 5A, B). Restoration of FSCN1 expression significantly rescued the proliferative, migratory, and invasive deficiencies induced by La/SSB loss, as shown by CCK-8, colony-formation, EdU, and Transwell assays (Figs. 5C–E, 5G). The increase in apoptosis caused by La/SSB depletion was also reversed upon FSCN1 re-expression (Fig. 5F).Fig. 5FSCN1 is a functionally important downstream target of La/SSB in HNSCC.shLa/SSB#1 FaDu cells and corresponding control cells were transduced with lentiviruses carrying either human FSCN1 cDNA or an empty vector. FSCN1 expression levels were evaluated by Western blot (A) and qRT-PCR (B). Cell proliferation was assessed using colony formation (C) and EdU incorporation assays (D). Scale bar: 100 μm. E Representative images of organoid diameters are shown. Scale bars: 400 μm (low magnification), 100 μm (high magnification); tumor organoid diameter quantification is based on n = 30 organoids, technical replicates. F Apoptosis was analyzed by flow cytometry. G Transwell assays were used to determine migration and invasion capacities. Scale bar: 100 μm. H–M The indicated FaDu cells were subcutaneously injected into mice to monitor tumor growth, with n = 5 mice per group. Representative tumor images (H), tumor weights (I), tumor volumes (J), and body weights (K) are presented. IHC staining of xenograft tissues for La/SSB, Ki-67, and cleaved caspase-3 is shown in (L). Scale bar: 50 μm. Quantitative analyses for La/SSB, FSCN1, Ki-67, and cleaved caspase-3 are presented in (M). N Representative images of lungs and H&E-stained sections illustrate metastatic lesions after tail vein injection, with n = 5 mice per group. Red arrowheads indicate metastatic nodules. Scale bars: 1 cm (gross lung images), 2 mm (H&E-stained lung sections). n = 3 independent biological replicates (B–D, F and G). Unpaired two-tailed Student’s t-test (A–G, I–K, M and N). Data are presented as mean ± SD where applicable. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. FSCN1 is a functionally important downstream target of La/SSB in HNSCC. shLa/SSB#1 FaDu cells and corresponding control cells were transduced with lentiviruses carrying either human FSCN1 cDNA or an empty vector. FSCN1 expression levels were evaluated by Western blot (A) and qRT-PCR (B). Cell proliferation was assessed using colony formation (C) and EdU incorporation assays (D). Scale bar: 100 μm. E Representative images of organoid diameters are shown. Scale bars: 400 μm (low magnification), 100 μm (high magnification); tumor organoid diameter quantification is based on n = 30 organoids, technical replicates. F Apoptosis was analyzed by flow cytometry. G Transwell assays were used to determine migration and invasion capacities. Scale bar: 100 μm. H–M The indicated FaDu cells were subcutaneously injected into mice to monitor tumor growth, with n = 5 mice per group. Representative tumor images (H), tumor weights (I), tumor volumes (J), and body weights (K) are presented. IHC staining of xenograft tissues for La/SSB, Ki-67, and cleaved caspase-3 is shown in (L). Scale bar: 50 μm. Quantitative analyses for La/SSB, FSCN1, Ki-67, and cleaved caspase-3 are presented in (M). N Representative images of lungs and H&E-stained sections illustrate metastatic lesions after tail vein injection, with n = 5 mice per group. Red arrowheads indicate metastatic nodules. Scale bars: 1 cm (gross lung images), 2 mm (H&E-stained lung sections). n = 3 independent biological replicates (B–D, F and G). Unpaired two-tailed Student’s t-test (A–G, I–K, M and N). Data are presented as mean ± SD where applicable. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. In vivo, FSCN1 re-expression in La/SSB-deficient FaDu cells restored xenograft tumor growth and lung-metastatic colonization, accompanied by elevated Ki-67 and reduced cleaved caspase-3 expression (Fig. 5H–N). Collectively, these results support FSCN1 as a functional downstream effector that phenocopies and may contribute to key La/SSB-associated tumor-promoting phenotypes in HNSCC. TFAP2C is associated with FSCN1 transcriptional regulation in HNSCC To explore the transcriptional connection between La/SSB and FSCN1, we performed integrated transcription-factor prediction and correlation analyses. Among candidate regulators identified from JASPAR and ChIP-Atlas databases, TFAP2C exhibited the strongest positive correlation with FSCN1 expression in the TCGA-HNSCC cohort (r = 0.214, P < 0.001; Fig. 6A–C). Further stratified analyses by HPV status supported that the positive correlation between TFAP2C and FSCN1 was consistently significant in both HPV-positive and HPV-negative subgroups. In contrast, SP1 showed no significant correlation with FSCN1 in either subgroup. For La/SSB, a significant positive correlation with FSCN1 was observed in the HPV-negative subgroup, but not in the HPV-positive subgroup, while no significant correlation was found between La/SSB and TFAP2C in either stratum. Consistently, all three genes were significantly upregulated in HPV-negative tumors compared with adjacent normal tissues (Fig. 6C; Supplementary Table S12). TFAP2C transcript and protein levels were significantly elevated in HNSCC tissues compared with adjacent mucosa, and higher expression was associated with advanced clinical stage and reduced OS (Fig. 6D, E).Fig. 6TFAP2C is associated with FSCN1 transcriptional regulation in HNSCC cells.A Venn diagram showing transcription factors positively associated with FSCN1 expression in the TCGA-HNSCC cohort. B Comparative analysis of TFAP2C and SP1 expression between ANM samples and HNSCC tumor tissues based on TCGA-HNSCC data. C Spearman’s correlation analyses of FSCN1 with TFAP2C and SP1 in the TCGA dataset, stratified by HPV status. D H-score quantification of IHC staining in 60 paired ANM and HNSCC tissues with representative images. Scale bar: 40 μm. E Kaplan–Meier survival analysis of 60 HNSCC patients stratified by median TFAP2C protein expression, with high (n = 30) and low (n = 30) groups, were compared using the log-rank test. F TFAP2C knockdown in FaDu cells and TFAP2C overexpression in TU177 cells were confirmed by western blotting, and the FSCN1 expression was evaluated by qRT-PCR and western blotting. G, H Representative images of tumor organoid diameters following TFAP2C knockdown or overexpression. Scale bars: 400 μm (low magnification), 100 μm (high magnification); PDO diameter quantification is based on n = 30 organoids, technical replicates. I Analysis of TFAP2C-binding peaks upstream of the FSCN1 promoter using ChIP-Atlas. J Schematic diagram depicting the predicted TFAP2C binding site within the FSCN1 promoter region. K ChIP-PCR assay assessing TFAP2C occupancy at the FSCN1 promoter in TU177 cells. L 293 T cells were co-transfected with WT or mutant FSCN1 promoter luciferase reporters together with TFAP2C expression plasmid or empty vector; luciferase activity was measured 24 h post-transfection. M ChIP assays in vector control and TFAP2C-overexpressing TU177 cells using TFAP2C antibodies or control IgG, with qRT-PCR amplification of regions flanking the predicted TFAP2C binding site in the FSCN1 promoter Results are expressed as the percentage of input DNA. n = 3 independent biological replicates (F, L and M). Unpaired two-tailed Student’s t-test (B and right panel of D, F–H, L and M). Paired two-tailed Student’s t-test (left panel of D). Data are presented as mean ± SD where applicable. ns, not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. TFAP2C is associated with FSCN1 transcriptional regulation in HNSCC cells. A Venn diagram showing transcription factors positively associated with FSCN1 expression in the TCGA-HNSCC cohort. B Comparative analysis of TFAP2C and SP1 expression between ANM samples and HNSCC tumor tissues based on TCGA-HNSCC data. C Spearman’s correlation analyses of FSCN1 with TFAP2C and SP1 in the TCGA dataset, stratified by HPV status. D H-score quantification of IHC staining in 60 paired ANM and HNSCC tissues with representative images. Scale bar: 40 μm. E Kaplan–Meier survival analysis of 60 HNSCC patients stratified by median TFAP2C protein expression, with high (n = 30) and low (n = 30) groups, were compared using the log-rank test. F TFAP2C knockdown in FaDu cells and TFAP2C overexpression in TU177 cells were confirmed by western blotting, and the FSCN1 expression was evaluated by qRT-PCR and western blotting. G, H Representative images of tumor organoid diameters following TFAP2C knockdown or overexpression. Scale bars: 400 μm (low magnification), 100 μm (high magnification); PDO diameter quantification is based on n = 30 organoids, technical replicates. I Analysis of TFAP2C-binding peaks upstream of the FSCN1 promoter using ChIP-Atlas. J Schematic diagram depicting the predicted TFAP2C binding site within the FSCN1 promoter region. K ChIP-PCR assay assessing TFAP2C occupancy at the FSCN1 promoter in TU177 cells. L 293 T cells were co-transfected with WT or mutant FSCN1 promoter luciferase reporters together with TFAP2C expression plasmid or empty vector; luciferase activity was measured 24 h post-transfection. M ChIP assays in vector control and TFAP2C-overexpressing TU177 cells using TFAP2C antibodies or control IgG, with qRT-PCR amplification of regions flanking the predicted TFAP2C binding site in the FSCN1 promoter Results are expressed as the percentage of input DNA. n = 3 independent biological replicates (F, L and M). Unpaired two-tailed Student’s t-test (B and right panel of D, F–H, L and M). Paired two-tailed Student’s t-test (left panel of D). Data are presented as mean ± SD where applicable. ns, not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. To evaluate the relationship between TFAP2C and FSCN1 transcription, we modulated TFAP2C expression in HNSCC cells. Silencing TFAP2C in FaDu cells markedly decreased FSCN1 mRNA and protein, whereas TFAP2C overexpression in TU177 cells induced robust FSCN1 up-regulation (Fig. 6F). In the PDO model established in this study, TFAP2C depletion suppressed organoid growth and proliferation, while TFAP2C overexpression enhanced these features, mirroring La/SSB-dependent phenotypes (Fig. 6G, H). Bioinformatic motif analysis revealed a high-affinity TFAP2C-binding site within the FSCN1 promoter region (Fig. 6I). ChIP assays supported TFAP2C enrichment at this site (Fig. 6J, K). Dual-luciferase reporter assays further demonstrated that TFAP2C correlates with elevated FSCN1 promoter activity in luciferase assays. In contrast, mutation of the binding site eliminated this effect (Fig. 6L). Parallel dual-luciferase reporter assays in FaDu and TU177 cells yielded consistent results (Fig. S7A, B). ChIP-qRT-PCR assays in TU177 cells supported that TFAP2C overexpression enhanced its enrichment at the FSCN1 promoter (Fig. 6M). In FaDu cells, La/SSB knockdown was associated with reduced enrichment of both TFAP2C and H3K27ac at this promoter region, with total TFAP2C protein levels remaining largely unchanged (Fig. S7C–E). ChIP-qRT-PCR data are summarized in Supplementary Table S13. These findings are consistent with a model in which La/SSB levels are associated with chromatin accessibility at the FSCN1 promoter, supporting a role for TFAP2C in regulating FSCN1 promoter activity. La/SSB depletion enhances CDDP sensitivity in a PDO model and La/ssbcKO mice Given the association of La/SSB with malignant phenotypes and CDDP response, we next investigated whether its depletion could potentiate the efficacy of CDDP, a first-line chemotherapy for HNSCC. In the patient-derived HNSCC organoid model established in this study, La/SSB knockdown significantly sensitized tumor organoids to CDDP treatment, producing greater suppression of viability than either intervention alone (Fig. 7A). IF staining showed pronounced decreases in Ki-67-positive cells and increases in cleaved-caspase-3-positive cells in the combination group, indicating enhanced apoptosis (Fig. 7B, C).Fig. 7La/SSB depletion enhances the antitumor effect of CDDP in PDO and in vivo models.A Cell viability of the PDO model established in this study treated with shLa/SSB and/or CDDP. Viability was assessed using the Cell-Titer Glo-3D assay. Scale bars: 100 μm (low magnification), 20 μm (high magnification). PDO viability quantification was based on n = 3 PDO technical replicates wells. Representative IF images showing La/SSB and Ki-67 (B) or La/SSB and cleaved caspase-3 (C) in PDO model established in this study. Scale bar: 20 μm. Quantifications shows the proportion of Ki-67-positive cells or cleaved caspase-3-positive cells (n = 5 fields, technical replicates). D Schematic of the experimental design for La/ssbcKO mice. La/ssbcKO mice were generated by crossing La/ssbfl/fl mice with Krt14Cre/ERT2 mice. After 16 weeks of 4NQO-induced tongue injury, tamoxifen was administered intraperitoneally to induce conditional knockout, followed by four weeks of CDDP treatment prior to euthanasia. Each experimental group included five mice (n = 5 mice per group). E Representative images of visible tongue lesions and quantification of lesion areas across treatment groups. Scale bar: 1 mm. F H&E-stained sections illustrating lesion histology and quantification of invasion grades. Scale bars: 100 μm (low magnification), 50 μm (high magnification). G IF images showing La/SSB (red) and Ki-67 (green) in tongue lesions, with DAPI-stained nuclei (blue). The percentage of Ki-67-positive cells per lesion is shown. Scale bar: 20 μm. H Representative IF images of La/SSB (green) and cleaved caspase-3 (red) in lesions. Scale bar: 20 μm. Unpaired two-tailed Student’s t-test (A–C, E–H). Data are presented as mean ± SD where applicable. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. La/SSB depletion enhances the antitumor effect of CDDP in PDO and in vivo models. A Cell viability of the PDO model established in this study treated with shLa/SSB and/or CDDP. Viability was assessed using the Cell-Titer Glo-3D assay. Scale bars: 100 μm (low magnification), 20 μm (high magnification). PDO viability quantification was based on n = 3 PDO technical replicates wells. Representative IF images showing La/SSB and Ki-67 (B) or La/SSB and cleaved caspase-3 (C) in PDO model established in this study. Scale bar: 20 μm. Quantifications shows the proportion of Ki-67-positive cells or cleaved caspase-3-positive cells (n = 5 fields, technical replicates). D Schematic of the experimental design for La/ssbcKO mice. La/ssbcKO mice were generated by crossing La/ssbfl/fl mice with Krt14Cre/ERT2 mice. After 16 weeks of 4NQO-induced tongue injury, tamoxifen was administered intraperitoneally to induce conditional knockout, followed by four weeks of CDDP treatment prior to euthanasia. Each experimental group included five mice (n = 5 mice per group). E Representative images of visible tongue lesions and quantification of lesion areas across treatment groups. Scale bar: 1 mm. F H&E-stained sections illustrating lesion histology and quantification of invasion grades. Scale bars: 100 μm (low magnification), 50 μm (high magnification). G IF images showing La/SSB (red) and Ki-67 (green) in tongue lesions, with DAPI-stained nuclei (blue). The percentage of Ki-67-positive cells per lesion is shown. Scale bar: 20 μm. H Representative IF images of La/SSB (green) and cleaved caspase-3 (red) in lesions. Scale bar: 20 μm. Unpaired two-tailed Student’s t-test (A–C, E–H). Data are presented as mean ± SD where applicable. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. To evaluate the in vivo therapeutic significance, conditional La/ssbcKO mice were produced by crossing La/ssbfl/fl mice with Krt14CreERT2 transgenic mice, followed by induction with tamoxifen (Fig. 7D). A Krt14CreERT2 + tamoxifen control group was included to control for potential Cre-dependent effects. Recombination efficiency was first verified by genomic PCR (Fig. S8A) and further supported at the protein level by IHC/IF, which showed markedly reduced La/SSB expression in Krt14-positive oral epithelial/tumor cells of cKO mice (Fig. S8E). Representative images and H&E staining of tumors from Krt14CreERT2 mice showed no overt abnormalities under saline or CDDP treatment (Fig. S8B–C). Histological examination of ANM samples further revealed no detectable epithelial abnormalities in Cre-only control mice, regardless of CDDP treatment (Fig. S8D). Tamoxifen was administered after 4NQO exposure, resulting in La/SSB deletion during tumor progression rather than tumor initiation. La/SSB deletion did not induce detectable histopathologic alterations or increased apoptosis in adjacent normal oral epithelium, and ANM samples exhibited comparable cleaved caspase-3 levels across groups following CDDP treatment (Fig. S8F). After 4-NQO-induced oral carcinogenesis, La/ssbcKO mice developed markedly fewer and smaller tongue lesions compared with control mice, and combination therapy with CDDP further reduced lesion burden (Fig. 7E). Histological analysis further showed reduced invasion grades after La/SSB deletion and CDDP treatment (Fig. 7F). IF analysis revealed reduced Ki-67 and increased cleaved caspase-3 staining in La/ssbcKO + CDDP lesions (Fig. 7G, H). These findings suggest that La/SSB loss is associated with enhanced CDDP responsiveness in this model, supporting the possibility that transient or context-selective suppression of La/SSB may improve CDDP response in HNSCC. Coordinated La/SSB, TFAP2C, and FSCN1 expression is linked to malignant progression and clinical outcome To assess the clinical relevance of this regulatory association, we analyzed La/SSB, TFAP2C, and FSCN1 expression in 60 paired HNSCC and adjacent normal samples. IHC analysis revealed positive correlations among the three proteins (Fig. 8A). ROC analyses were used to evaluate the ability of La/SSB expression to distinguish tumor from non-tumor tissues and were not intended to assess prognostic performance; prognostic relevance was evaluated separately using Kaplan–Meier and Cox regression analyses. ROC curve analyses revealed strong diagnostic performance for distinguishing tumor from adjacent normal tissues, with AUCs of 0.872 for La/SSB, 0.868 for TFAP2C, and 0.862 for FSCN1 (Fig. 8B). Consistent trends were observed in the TCGA-HNSCC cohort (AUC = 0.844, 0.619, 0.948, respectively; Fig. 8C). Representative IHC staining demonstrated that tumor regions with intense La/SSB expression exhibited concurrent nuclear TFAP2C accumulation and elevated cytoplasmic FSCN1 levels (Fig. 8D). A schematic model summarizes the proposed La/SSB–TFAP2C–FSCN1 regulatory association in HNSCC, linking La/SSB activity to FSCN1-driven proliferation, invasion, apoptosis resistance, and CDDP resistance (Fig. 8E). In support of these findings, Kaplan–Meier and multivariable Cox regression analyses in the TCGA-HNSCC cohort were performed to evaluate prognostic relevance. Multivariable Cox regression analysis identified La/SSB as an independent prognostic factor after adjustment for key clinicopathological covariates. High FSCN1 expression was also associated with shorter OS (P < 0.05). By contrast, TFAP2C expression alone showed no significant prognostic effect (all P > 0.05) (Supplementary Table S14). La/SSB showed independent prognostic value in multivariable analysis, whereas TFAP2C and FSCN1 were associated with clinical features and/or survival trends but did not independently predict outcome.Fig. 8Coordinated expression of La/SSB, TFAP2C, and FSCN1 is associated with malignant progression and clinical outcome in HNSCC.A Spearman’s correlation analysis among La/SSB, TFAP2C, and FSCN1 expression levels in 60 HNSCC tissue samples. Correlation coefficients are indicated in the upper-right corners. Scatterplot matrices with fitted regression lines for the respective gene pairs are shown in the lower-left panels. ROC curves for tumor-versus-normal discrimination of La/SSB, TFAP2C, and FSCN1 expression based on H-scores from 60 HNSCC patient tissues (B) and TCGA cohort data (C). D Representative IHC images of La/SSB, TFAP2C, and FSCN1 in HNSCC tissues. Scale bar, 100 μm. E Schematic model summarizing the association among La/SSB, TFAP2C, and FSCN1 in HNSCC progression, including proliferation, migration, apoptosis, and chemoresistance. **P < 0.01, ***P < 0.001. Coordinated expression of La/SSB, TFAP2C, and FSCN1 is associated with malignant progression and clinical outcome in HNSCC. A Spearman’s correlation analysis among La/SSB, TFAP2C, and FSCN1 expression levels in 60 HNSCC tissue samples. Correlation coefficients are indicated in the upper-right corners. Scatterplot matrices with fitted regression lines for the respective gene pairs are shown in the lower-left panels. ROC curves for tumor-versus-normal discrimination of La/SSB, TFAP2C, and FSCN1 expression based on H-scores from 60 HNSCC patient tissues (B) and TCGA cohort data (C). D Representative IHC images of La/SSB, TFAP2C, and FSCN1 in HNSCC tissues. Scale bar, 100 μm. E Schematic model summarizing the association among La/SSB, TFAP2C, and FSCN1 in HNSCC progression, including proliferation, migration, apoptosis, and chemoresistance. **P < 0.01, ***P < 0.001. Discussion The present study identifies La/SSB as a putative oncogenic regulator in HNSCC. Through multi-omics integration and multi-model validation, we show that La/SSB is associated with altered tumor transcriptional activity, including TFAP2C-associated regulation of FSCN1, consistent with a potential coupling between RNA-binding dynamics and chromatin-associated gene regulation. This work expands the functional paradigm of RNA-binding proteins beyond their canonical post-transcriptional roles, positioning La/SSB as a potential correlative link among RNA metabolism, cytoskeletal remodeling, and chemotherapeutic resistance in HNSCC. La/SSB was originally described as an autoimmune antigen in Sjögren syndrome, but accumulating evidence indicates that its dysregulation contributes to tumorigenesis [8, 9, 22–24]. Increased La/SSB expression has been observed in hepatocellular carcinoma, breast cancer, and non-small-cell lung cancer, where it stabilizes oncogenic mRNAs and sustains translation under stress[11, 25–27]. Our findings extend this oncogenic landscape to HNSCC, showing that La/SSB upregulation correlates with advanced disease and poor prognosis. Importantly, its loss attenuates tumor growth and metastatic potential across both in vitro and in vivo systems, supporting a context-dependent functional role for La/SSB in HNSCC progression. These data highlight La/SSB as a member of an emerging class of RBPs that may exert transcription-associated regulatory functions, potentially through modulation of chromatin-associated complexes. Mechanistically, our integrative RNA-seq and ATAC-seq analyses implicate FSCN1 as the functionally relevant downstream effector of La/SSB. FSCN1 encodes an actin-bundling protein essential for the formation of filopodia and invadopodia, cellular structures that enable motility and invasion [28–31]. In normal epithelia, FSCN1 expression is tightly suppressed, whereas its reactivation is a hallmark of metastatic carcinomas [32, 33]. La/SSB depletion was accompanied by reduced promoter-associated chromatin accessibility signals at the FSCN1 locus, although this locus-level ATAC-seq change did not meet FDR-adjusted significance and should therefore be interpreted as supportive rather than definitive evidence. The observation that La/SSB silencing is associated with reduced FSCN1 promoter accessibility, together with the ability of FSCN1 restoration to rescue La/SSB loss-of-function phenotypes, supports a functional relationship between these factors. This epistatic relationship is consistent with a model in which La/SSB may contribute to cytoskeletal plasticity through transcription-associated regulatory programs rather than solely through mRNA stabilization. Upstream of FSCN1, we identified TFAP2C as a potential transcriptional intermediary that may contribute to La/SSB-associated promoter-specific gene regulation. TFAP2C is a context-dependent transcription factor known to remodel chromatin accessibility and coordinate oncogenic programs such as epithelial–mesenchymal transition and therapy resistance [34–37]. Prior studies have shown that TFAP2C cooperates with lineage-specific factors like p63 or GATA3 to shape enhancer landscapes in epithelial tumors [38–40]. Our data now suggest that La/SSB is associated with altered TFAP2C occupancy at the FSCN1 promoter, potentially through modulation of chromatin accessibility and transcription factor recruitment. This crosstalk exemplifies a broader principle whereby RBPs indirectly dictate transcriptional outcomes by influencing transcription factor loading and nucleosome accessibility. Because the luciferase reporter was based on a 190-bp promoter fragment, this assay supports local promoter responsiveness but does not capture the full regulatory complexity of the endogenous FSCN1 locus. However, these findings do not establish direct causality, and the precise mechanism by which La/SSB influences TFAP2C recruitment remains to be fully defined. In addition, although TFAP2C may contribute to FSCN1 transcription, other downstream transcriptional regulators cannot be excluded. La/SSB is best known as an RNA chaperone for RNA polymerase III transcripts, thereby supporting translational capacity and anabolic fitness. Our findings do not replace this canonical function. Rather, they suggest that La/SSB-high HNSCC cells may couple enhanced RNA metabolic capacity with a non-canonical transcription-associated program involving TFAP2C/FSCN1-linked regulation. We therefore view the La/SSB–TFAP2C–FSCN1 regulatory network not as a replacement for the canonical Pol III pathway, but as an additional regulatory layer that may act in parallel to promote HNSCC progression and therapy resistance. Defining the relative contribution and potential crosstalk between these pathways will be an important subject for future studies. Functionally, La/SSB also confers protection against genotoxic stress, contributing to CDDP resistance. Platinum compounds induce DNA crosslinks and activate DNA-damage response pathways, leading to apoptosis in sensitive cells. The survival advantage conferred by La/SSB may involve its established role in stress-adaptive RNA metabolism, although the precise downstream transcripts remain to be defined. Genetic depletion of La/SSB markedly enhanced CDDP efficacy in organoid and conditional-knockout models, suggesting that targeting La/SSB may disrupt this adaptive translational network. These findings align with prior reports that RBPs such as IGF2BP2 or YBX1 mediate similar resistance programs, reinforcing the idea that translational plasticity constitutes a major determinant of chemoresistance in epithelial malignancies [41]. Our model primarily evaluates tumor progression rather than tumor initiation, as La/SSB deletion is induced after 4NQO treatment and early tumor formation. Conceptually, the La/SSB–TFAP2C–FSCN1 regulatory network delineated here supports a model of multilayer regulation, in which an RNA-binding protein indirectly is associated with transcription-associated regulation to promote cytoskeletal reorganization, invasion, and therapeutic evasion. This dual control over RNA fate and chromatin accessibility may represent a general strategy exploited by tumors to sustain malignant phenotypes under environmental and therapeutic stress. From a translational perspective, La/SSB may represent a context-dependent vulnerability rather than a conventional systemic target in HNSCC. Future therapeutic strategies may therefore require transient, tumor-selective, or locally delivered interventions, particularly in combination with CDDP, to maximize efficacy while minimizing toxicity to normal tissues. Importantly, the frequent classification of La/SSB as a common-essential gene highlights the need for precision delivery strategies and careful therapeutic window optimization. Beyond direct targeting, the coordinated expression pattern of La/SSB, TFAP2C, and FSCN1 may also serve as a clinically relevant biomarker framework for risk stratification and treatment guidance. Several limitations should be acknowledged. First, although PDO-based experiments provide clinically relevant functional evidence, validation was performed in a single PDO line, and broader validation across multiple independent PDO models is required. Second, while integrative epigenomic analyses suggest associations between La/SSB, chromatin accessibility, and TFAP2C occupancy, the precise molecular mechanism remains incompletely defined. Third, the ATAC-seq signal at the FSCN1 promoter did not reach genome-wide significance thresholds and should be interpreted cautiously. Despite these limitations, the integrated data support a model in which La/SSB is associated with TFAP2C-linked transcriptional regulation of FSCN1, thereby promoting tumor progression and chemoresistance in HNSCC. Collectively, our findings support a multilayer regulatory framework in which an RNA-binding protein is functionally associated with transcriptional and chromatin-level regulation, contributing to malignant phenotypes and therapeutic response. Supplementary information Supplementary Figures S1–S8 Supplementary Table S1-S7,S10-12 Supplementary Table S8 Supplementary Table S9 Supplementary Table S13 Supplementary Table S14 Supplementary Figures S1–S8 Supplementary Table S1-S7,S10-12 Supplementary Table S8 Supplementary Table S9 Supplementary Table S13 Supplementary Table S14